Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eighteen research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $178.57.
RGEN has been the topic of several research analyst reports. Royal Bank Of Canada upped their price objective on Repligen from $185.00 to $200.00 and gave the company an "outperform" rating in a research report on Wednesday, October 28th. Barclays lifted their target price on Repligen from $175.00 to $225.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. UBS Group reiterated a "buy" rating on shares of Repligen in a research report on Tuesday, September 29th. Weiss Ratings lowered shares of Repligen from a "hold (c)" rating to a "sell (d+)" rating in a research note on Monday, November 2nd. Finally, Wells Fargo & Company upped their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th.
Get Our Latest Stock Report on Repligen
Repligen Stock Down 0.4%
Shares of NASDAQ RGEN opened at $162.18 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 8.43. The company has a market cap of $10.37 billion, a P/E ratio of -772.25, a PEG ratio of 2.79 and a beta of 1.11. Repligen has a 1 year low of $100.99 and a 1 year high of $198.87. The firm has a 50-day simple moving average of $176.92 and a two-hundred day simple moving average of $145.71.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The firm had revenue of $209.31 million for the quarter, compared to analysts' expectations of $206.70 million. During the same quarter in the prior year, the firm posted $0.46 earnings per share. The company's quarterly revenue was up 10.9% on a year-over-year basis. Research analysts anticipate that Repligen will post 2.07 earnings per share for the current year.
Hedge Funds Weigh In On Repligen
A number of hedge funds have recently added to or reduced their stakes in RGEN. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $380,756,000. Wasatch Advisors LP boosted its position in Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after purchasing an additional 346,720 shares in the last quarter. Maverick Capital Ltd. bought a new stake in Repligen during the first quarter valued at about $178,946,000. William Blair Investment Management LLC grew its stake in Repligen by 57.7% in the third quarter. William Blair Investment Management LLC now owns 1,243,415 shares of the biotechnology company's stock valued at $239,022,000 after purchasing an additional 454,844 shares during the last quarter. Finally, Congress Asset Management Co. grew its stake in Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company's stock valued at $196,249,000 after purchasing an additional 8,681 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.
About Repligen
(
Get Free Report)
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company's offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.